Title: 2025-2026 Regular Session HR 137 PN 1067 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN1067
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HR 137 PN 1067 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1067 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.137 Session of 2025 INTRODUCED BY MALAGARI, HILL-EVANS, FREEMAN, VENKAT, GIRAL, KHAN, HADDOCK, SANCHEZ, CONKLIN, D. WILLIAMS, GREEN AND CURRY, MARCH 19, 2025 REFERRED TO COMMITTEE ON HEALTH, MARCH 19, 2025 A RESOLUTIONRecognizing May 17, 2025, as "World Neurofibromatosis Awareness Day" in Pennsylvania.WHEREAS, The Children's Tumor Foundation annually observes May 17 as "World Neurofibromatosis Awareness Day" to educate the public about this rare genetic condition; andWHEREAS, The global community recognizes the importance of raising awareness about neurofibromatosis, its impact on individuals and families and the need for continued research and support; andWHEREAS, Although more than 4 million people around the world are living with neurofibromatosis and 1 in every 2,000 births is diagnosed with neurofibromatosis, it is still relatively unknown to the public; andWHEREAS, Neurofibromatosis affects all populations equally, regardless of race, ethnicity or gender; andWHEREAS, Neurofibromatosis causes tumors to grow on nerves throughout the body and also can affect development of the 1234567891011121314151617 brain, cardiovascular system, bones and skin; andWHEREAS, The disorder can lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain and cancer; andWHEREAS, There are three different types of neurofibromatosis: neurofibromatosis type 1, neurofibromatosis type 2 and schwannomatosis; andWHEREAS, Signs of neurofibromatosis type 1 include light brown spots on the skin, known as café au lait spots, bumps known as Lisch nodules on the iris of the eye and freckles on the groin or armpits; andWHEREAS, Neurofibromatosis type 1 is one of the country's most common genetic disorders occurring in approximately 1 in 2,500 births; andWHEREAS, Neurofibromatosis type 2 is far less common, occurring in 1 in 60,000 people, and is typically characterized by tumors that grow on the nerves of the inner ear; andWHEREAS, Schwannomatosis is a rarer form of neurofibromatosis for which symptoms typically appear between ages 25 and 30; andWHEREAS, Schwannomatosis often forms on the spinal or cranial nerves and leads to symptoms like chronic pain or loss of muscle; andWHEREAS, Instances of neurofibromatosis occur due to mutations that either occur during conception or are passed down genetically through the parents; andWHEREAS, Family history, physical exams and genetic tests are currently used to diagnose neurofibromatosis in patients; andWHEREAS, While there is currently no cure available, there are multiple forms of treatment for patients dealing with neurofibromatosis; and20250HR0137PN1067 - 2 - 123456789101112131415161718192021222324252627282930 WHEREAS, Mild instances of neurofibromatosis often do not require significant treatment outside of regular doctor visits and observation; andWHEREAS, More severe cases may require removal through radiation or surgery done by a nerve tumor specialist or a team of various surgeons; andWHEREAS, There are currently no medications that have been approved to treat neurofibromatosis, though researchers are investigating various methods and therapies; andWHEREAS, The Children's Tumor Foundation leads efforts to promote and financially sponsor world-class medical research aimed at finding effective treatments and, ultimately, a cure for neurofibromatosis; andWHEREAS, The Children's Tumor Foundation is connecting the unconnected, leading the way through innovative and inventive approaches to scientific advancement and improved patient care, revamping systems to accelerate the path from discovery to treatment; andWHEREAS, The Children's Tumor Foundation provides patient and family support through its information resources, youth programs and community activities; andWHEREAS, Much remains to be done in raising public awareness of neurofibromatosis to help promote early diagnosis, proper management and treatment, prevention of complications and support for research; therefore be itRESOLVED, That the House of Representatives recognize May 17, 2025, as "World Neurofibromatosis Awareness Day" in Pennsylvania.20250HR0137PN1067 - 3 - 12345678910111213141516171819202122232425262728


================================================================================

Raw Text:
2025-2026 Regular Session HR 137 PN 1067 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1067 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.137 Session of 2025 INTRODUCED BY MALAGARI, HILL-EVANS, FREEMAN, VENKAT, GIRAL, KHAN, HADDOCK, SANCHEZ, CONKLIN, D. WILLIAMS, GREEN AND CURRY, MARCH 19, 2025 REFERRED TO COMMITTEE ON HEALTH, MARCH 19, 2025 A RESOLUTIONRecognizing May 17, 2025, as "World Neurofibromatosis Awareness Day" in Pennsylvania.WHEREAS, The Children's Tumor Foundation annually observes May 17 as "World Neurofibromatosis Awareness Day" to educate the public about this rare genetic condition; andWHEREAS, The global community recognizes the importance of raising awareness about neurofibromatosis, its impact on individuals and families and the need for continued research and support; andWHEREAS, Although more than 4 million people around the world are living with neurofibromatosis and 1 in every 2,000 births is diagnosed with neurofibromatosis, it is still relatively unknown to the public; andWHEREAS, Neurofibromatosis affects all populations equally, regardless of race, ethnicity or gender; andWHEREAS, Neurofibromatosis causes tumors to grow on nerves throughout the body and also can affect development of the 1234567891011121314151617 brain, cardiovascular system, bones and skin; andWHEREAS, The disorder can lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain and cancer; andWHEREAS, There are three different types of neurofibromatosis: neurofibromatosis type 1, neurofibromatosis type 2 and schwannomatosis; andWHEREAS, Signs of neurofibromatosis type 1 include light brown spots on the skin, known as café au lait spots, bumps known as Lisch nodules on the iris of the eye and freckles on the groin or armpits; andWHEREAS, Neurofibromatosis type 1 is one of the country's most common genetic disorders occurring in approximately 1 in 2,500 births; andWHEREAS, Neurofibromatosis type 2 is far less common, occurring in 1 in 60,000 people, and is typically characterized by tumors that grow on the nerves of the inner ear; andWHEREAS, Schwannomatosis is a rarer form of neurofibromatosis for which symptoms typically appear between ages 25 and 30; andWHEREAS, Schwannomatosis often forms on the spinal or cranial nerves and leads to symptoms like chronic pain or loss of muscle; andWHEREAS, Instances of neurofibromatosis occur due to mutations that either occur during conception or are passed down genetically through the parents; andWHEREAS, Family history, physical exams and genetic tests are currently used to diagnose neurofibromatosis in patients; andWHEREAS, While there is currently no cure available, there are multiple forms of treatment for patients dealing with neurofibromatosis; and20250HR0137PN1067 - 2 - 123456789101112131415161718192021222324252627282930 WHEREAS, Mild instances of neurofibromatosis often do not require significant treatment outside of regular doctor visits and observation; andWHEREAS, More severe cases may require removal through radiation or surgery done by a nerve tumor specialist or a team of various surgeons; andWHEREAS, There are currently no medications that have been approved to treat neurofibromatosis, though researchers are investigating various methods and therapies; andWHEREAS, The Children's Tumor Foundation leads efforts to promote and financially sponsor world-class medical research aimed at finding effective treatments and, ultimately, a cure for neurofibromatosis; andWHEREAS, The Children's Tumor Foundation is connecting the unconnected, leading the way through innovative and inventive approaches to scientific advancement and improved patient care, revamping systems to accelerate the path from discovery to treatment; andWHEREAS, The Children's Tumor Foundation provides patient and family support through its information resources, youth programs and community activities; andWHEREAS, Much remains to be done in raising public awareness of neurofibromatosis to help promote early diagnosis, proper management and treatment, prevention of complications and support for research; therefore be itRESOLVED, That the House of Representatives recognize May 17, 2025, as "World Neurofibromatosis Awareness Day" in Pennsylvania.20250HR0137PN1067 - 3 - 12345678910111213141516171819202122232425262728